Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Polyrizon completes site contracts for NASARIX first-in-human allergy study

Polyrizon (NASDAQ: PLRZ) has completed contracting with the fourth and fifth U.S. clinical sites participating in its study of NASARIX Allergy Blocker (PL-14), moving the program into study execution. The planned first...

September 2, 2026

Developments

cbdMD to acquire Twinlab brands

cbdMD (NYSE American: YCBD) has announced that it has entered into a definitive asset purchase agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea...

September 2, 2026

Developments

USPTO issues NOA for Purple’s next-gen multispecific antibody platform

Purple Biotech (NASDAQ/TASE: PPBT) has announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent application covering tri-specific antibody constructs and methods of use...

September 2, 2026

Executive Moves

Valion announces changes to management and BOD

Valion Bio (NASDAQ: VBIO) has announced that its current chief financial officer, Lisa Wolf, has also been named president and chief operating officer, effective immediately, following the departure of former chief...

September 1, 2026

Executive Moves

Profound strengthens leadership team with appointment of Richard Fabian as president

Profound Medical (NASDAQ: PROF; TSX: PRN) has appointed Richard Fabian as president, effective immediately, succeeding Mathieu Burtnyk, PhD, who has assumed the newly created position of chief technology officer. Mr...

September 1, 2026

Developments

Karyopharm submits sNDA for XPOVIO + ruxolitinib in MF

Karyopharm Therapeutics (NASDAQ: KPTI) has announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA seeking accelerated approval for XPOVIO (selinexor) in combination with ruxolitinib for...

August 31, 2026

Developments

TELA announces COO/CFO transition and cost reduction

TELA Bio (NASDAQ: TELA) has announced that Roberto Cuca, chief operating officer and chief financial officer (COO/CFO), will step down from the role effective today. In a statement, Heather Getz, CEO of TELA, commented...

August 31, 2026

Developments

Aprea announces IP expansion for precision oncology programs

Aprea Therapeutics (NASDAQ: APRE) has announced an expansion of its intellectual property (IP) portfolio for precision oncology programs. According to Aprea, the company has strengthened its global IP portfolio with 28...

August 28, 2026

Developments

Quoin reports positive interim data from study of topical treatment for NS

Quoin Pharmaceuticals (NASDAQ: QNRX) has announced positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome (NS), a rare, genetic skin disease...

August 28, 2026

Developments

BrainsWay Deep TMS study shows 70% reduction in suicidal ideation in MDD

BrainsWay (NASDAQ: BWAY; TASE: BWAY) has announced the publication of new peer-reviewed data in the Journal of Affective Disorders demonstrating significant reductions in suicidal ideation among patients with major...

August 27, 2026

Executive Moves

Healthcare investor veteran Greg Ciongoli joins REGENXBIO’s board

REGENXBIO (NASDAQ: RGNX) has announced the appointment of Greg Ciongoli to its board of directors, effective August 25, 2026. Mr. Ciongoli brings extensive experience in biotechnology investing, capital allocation, and...

August 26, 2026

Developments

Precision doses first patient in study of in vivo gene editing program in DMD

Precision Biosciences (NASDAQ: DTIL) has announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating its in vivo gene editing program, PBGENE-DMD, for the treatment of...

August 25, 2026

Subscribe